Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Effect of Food on PK of Sitravatinib in Healthy Adults
NCT04800614Phase 1Completed
- Sponsor
- Mirati Therapeutics
- Start
- Mar 2021
- Primary completion
- Jul 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of sitravatinib in non-small cell lung cancer (NSCLC) (6 arms), sponsored by Mirati Therapeutics. Primary endpoints: Maximum Plasma Concentration at 72 hours, Area Under the Curve from time zero to infinity at 72 hours and 1 more. Started Mar 2021; status: completed.
02
Drugs
sitravatinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT04800614.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04800614.